Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, ArcticZymes Technologies ASA's average EBITDA Per Share Growth Rate was 12900.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -23.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -22.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of ArcticZymes Technologies ASA was 105.70% per year. The lowest was -35.10% per year. And the median was 11.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ArcticZymes Technologies ASA 3-Year EBITDA Growth Rate Related Terms
LTS:0DRV vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, ArcticZymes Technologies ASA's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArcticZymes Technologies ASA 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ArcticZymes Technologies ASA's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -23.60% mean?
ArcticZymes Technologies ASA (LTS:0DRV) has a 3-Year EBITDA Growth Rate of -23.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ArcticZymes Technologies ASA and its competitors. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #987 out of 1124 companies in the Biotechnology industry, placing it in the top 87.8%.
Is ArcticZymes Technologies ASA's 3-Year EBITDA Growth Rate too high?
ArcticZymes Technologies ASA's current 3-Year EBITDA Growth Rate is -23.60%. Based on the distribution chart, ArcticZymes Technologies ASA ranks #987 out of 1124 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #987 out of 1124 companies for 3-Year EBITDA Growth Rate. This places ArcticZymes Technologies ASA in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,124 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ArcticZymes Technologies ASA and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ArcticZymes Technologies ASA's current 3-Year EBITDA Growth Rate is -23.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA (LTS:0DRV) is currently considered Modestly Undervalued. The stock's GF Value™ is kr26.45, compared to a current price of kr21.20 — trading 19.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -23.60%. ArcticZymes Technologies ASA's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ArcticZymes Technologies ASA (LTS:0DRV), the current 3-Year EBITDA Growth Rate is -23.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of kr21.20 is trading 19.8% below its estimated GF Value™ of kr26.45.
GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.
Key valuation signals for LTS:0DRV:
3-Year EBITDA Growth Rate: -23.60%
GF Value™: kr26.45 vs. price of kr21.20 (19.8% below fair value)
No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
72GF Score
Get the complete analysis for LTS:0DRV
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRV has been successfully added to your 
